申请人:CHUGAI SEIYAKU KABUSHIKI KAISHA
公开号:EP1219631A1
公开(公告)日:2002-07-03
Compounds represented by the general formula (I), pharmaceutically acceptable salts thereof, or prodrugs of the compounds or their salts:
[wherein X1 and X2 represent independently a hydrogen atom or a group represented by the general formula (II)
-Ar-A-R1 (II)
Ra represents a hydrogen atom or a protective group of a hydroxyl group, Rb and Rc, when taken together with the carbon atom in 3-position to which they are bound, represent an optionally protected -(C=O)-, and the dashed line in combination with the solid line represents the formation of a single bond or a double bond;
in addition, Ar represents a single bond or an aromatic hydrocarbon group, A represents a methylene group or -O-, R1 represents an optionally substituted alkyl group, an optionally substituted alkenyl group or an optionally substituted alkynyl group;
provided that X1 and X2 are not a hydrogen atom at the same time], as well as substances that act as antagonist against but not as agonist for the androgen receptor, pharmaceutically acceptable salts thereof, or prodrugs of the substances or their salts are useful as antiandrogenic agents and may be used as preventives or therapeutics of a disease selected from prostate cancer, prostatomegaly, male pattern alopecia, sexual prematurity, acne vulgaris, seborrhea and hursutism.
通式(I)代表的化合物、其药学上可接受的盐,或化合物或其盐的原药:
[其中 X1 和 X2 独立地代表氢原子或通式(II)所代表的基团
-Ar-A-R1 (II)
Ra 代表氢原子或羟基的保护基团,Rb 和 Rc 与它们所结合的位于 3 位的碳原子结合在一起时,代表任选保护的-(C=O)-,虚线与实线结合代表形成单键或双键;
此外,Ar 代表单键或芳香烃基,A 代表亚甲基或-O-,R1 代表任选取代的烷基、任选取代的烯基或任选取代的炔基;
条件是 X1 和 X2 不是同时为氢原子],以及可作为雄激素受体拮抗剂但不作为雄激素受体激动剂的物质、其药学上可接受的盐、或这些物质或其盐的原药可作为抗雄激素制剂,并可用作选自前列腺癌、前列腺肥大、男性型脱发、性早熟、寻常痤疮、脂溢性脱发和胡须增多症的疾病的预防或治疗剂。